FDA Adverse Event Injury Summary report: N

COMPOSIX MESH E/X

MDR report key: 2021331 · Received March 8, 2011

Report

Report Number
1213643-2011-00064
Event Type
Injury
Date Received
March 8, 2011
Date of Event
June 1, 2009
Report Date
February 11, 2011
Manufacturer
DAVOL INC., SUB. C.R. BARD, INC.
Product Code
FTL
PMA / PMN Number
K002684
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NY, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

WE HAVE CONTACTED THE INITIAL RPTR TO REQUEST ADDITIONAL INFO AND TO REQUEST RETURN OF THE DEVICE FOR EVAL. THIS MDR INCLUDES ALL PT, EVENT AND DEVICE INFO DAVOL HAS RECEIVED TO DATE. THE ATTORNEY'S REPORT INDICATES THAT THE PT HAD AND WAS TREATED FOR A RECURRENCE, WHICH IS A KNOWN POSSIBLE ADVERSE EVENT LISTED IN THE IFU. HOWEVER, IT IS UNK WHETHER OR NOT THE DEVICE MAY HAVE CAUSED OR CONTRIBUTED TO THE EVENT BASED ON THE INFO CURRENTLY AVAILABLE. FURTHERMORE, NO PRODUCT HAS BEEN RETURNED NOR HAS A SPECIFIC PRODUCT PROBLEM BEEN REPORTED. NO CONCLUSION CAN BE DRAWN AT THIS TIME.

Description of Event or Problem · 1

ATTORNEY REPORTED: ON (B)(6) 2006: PT PRESENTED TO THE HOSPITAL FOR REPAIR OF AN INGUINAL HERNIA, WITH PLACEMENT OF A BARD COMPOSIX EX MESH. ON (B)(6) 2009: PT PRESENTED TO THE HOSPITAL WITH COMPLAINTS OF ABDOMINAL PAIN AND A RECURRENCE OF A RIGHT INGUINAL HERNIA. DURING SURGERY, SURGEON FOUND ADHESIONS ATTACHED TO THE PREVIOUSLY PLACED MESH AND CAREFULLY REMOVED THEM. THE SURGICAL PATHOLOGY REPORTED A SPECIMEN CONSISTED OF MESH ADHESIONS FOREIGN BODY GIANT CELL REACTION. ONCE THE ADHESIONS WERE REMOVED, PT'S HERNIA WAS REPAIRED. PT HAS SUFFERED AND WILL CONTINUE TO SUFFER PHYSICAL PAIN. PT SUFFERED SERIOUS PERMANENT INJURIES, PAIN AND SUFFERING. PT DEVELOPED SERIOUS PHYSICAL COMPLICATIONS AND ULTIMATELY REQUIRED HIM TO HAVE A SUBSEQUENT SURGERY TO REMOVE THE DEFECTIVE MESH.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 COMPOSIX MESH E/X FTL DAVOL INC., SUB. C.R. BARD, INC. NA NI

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention